N-[2-(4-methoxyphenyl)ethyl]-2-quinoxalinecarboxamide and Lung-Neoplasms

Stearoyl-CoA desaturase (SCD) catalyzes the first step in the conversion of saturated fatty acids to unsaturated fatty acids. Unsaturated fatty acids are required for membrane integrity and for cell proliferation. For these reasons, inhibitors of SCD represent potential treatments for cancer. However, systemically active SCD inhibitors result in skin toxicity, which presents an obstacle to their development. We recently described a series of oxalic acid diamides that are converted into active SCD inhibitors within a subset of cancers by CYP4F11-mediated metabolism. Herein, we describe the optimization of the oxalic acid diamides and related N-acyl ureas and an analysis of the structure-activity relationships related to metabolic activation and SCD inhibition.

Topics: Animals; Cell Line, Tumor; Cytochrome P450 Family 4; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Mice, Inbred Strains; Oxalic Acid; Small Molecule Libraries; Stearoyl-CoA Desaturase; Structure-Activity Relationship